ClinicalTrials.gg
RecruitingNCT06364449Updated Jun 19, 2025

Clinical Decision Tree Analysis of Hemodialysis Arteriovenous Access Choices and Creations - a Multiple-center Retrospective Cohort Study

An observational study in Decision Tree Analysis, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Arteriovenous Fistula with a site in Taiwan — 2 open to participants now, 3 under way, none of them phase 3. Arteriovenous Fistula · Taiwan.

Started
2023
with 2 others
Observational
6 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
5 of 10
National Taiwan University Hospital

Among the 10 studies in Arteriovenous Fistula with a site in Taiwan, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 8th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

2 of the 10 studies in Arteriovenous Fistula with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arteriovenous Fistula with a site in Taiwan, or all of them as a file.
02

Study summary

Our study aim was to utilize a decision tree analysis (DTA) model to gain insight into the decision-making process within a multiple-center cohort.

Read the detailed description

Scientific research focuses on limited parameters, aims to confirm hypotheses, and has minor uncertainties. In contrast, medical decisions involve many unknowns. Physicians must use all available knowledge to make the best decisions. However, decision-making can become unpredictable when limited evidence exists, leading to non-reproducible outcomes.

According to clinical guidelines, patients who need pre-kidney replacement therapy (pre-KRT) and opt for hemodialysis (HD) with a reasonable life expectancy should have arteriovenous (AV) access created. Nevertheless, constructing an AVF has limitations. [Additionally, the maturation rate of AVF is suboptimal. Therefore, after careful consideration of the patient's end-stage kidney disease (ESKD) life plan, the suggested order of AV access types and locations starts a native distal forearm radiocephalic AVF, followed by a native proximal forearm AVF, a forearm arteriovenous graft (AVG), then an upper arm AVG creation.[Lok et al., 2020] However, the decision-making process for selecting hemodialysis access is shared between patients, physicians, and the surgeon's discretion.

Therefore, clinical kidney practice requires effective decision-making to address ESKD life plan and AV access concerns while minimizing harm. Decision analysis models can bridge the gap between research and decision-making. Our study aim was to utilize a decision tree analysis (DTA) model to gain insight into the decision-making process within a multiple-center cohort.

03

Conditions studied

  • Decision Tree Analysis

Browse trials for

Keywords

  • Arteriovenous Fistula
  • AV graft
  • Hemodialysis
  • decision tree analysis
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

chronic kidney disease (CKD) and were in the pre-kidney replacement therapy (pre-KRT) stage, requiring their first hemodialysis (HD) AV access creatio

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients between the ages of 18 and 80 who were referred for primary hemodialysis (HD) AV access creation. We included those in the pre-kidney replacement therapy (pre-KRT) stage and those who in the early end-stage kidney disease (ESKD) urgently started HD without sufficient time to plan for AV access

Exclusion criteria

Exclusion Criteria:

  • patients who underwent a secondary AV access surgery, like a transposed radiobasilic AVF or a revision of AVG.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • AVF-wrist

    Other: No intervention

  • AVF-elbow

    Other: No intervention

  • AVG-forearm

    Other: No intervention

  • AVG-elbow

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. predicted AV access choices

    identifying parameters that predicted AV access choices among the four types

    Time frame: postoperativ 3 -12 months

Secondary outcomes

  1. to determine factors affecting clinical use of the targeted AV access over a variable timeframe

    The secondary objective was to determine factors affecting clinical use of the targeted AV access over a variable timeframe

    Time frame: postoperativ 3 -12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in May 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 15, 2024
StartActual
Oct 13, 2023
Primary completionActual
May 7, 2024
CompletionEst.
Jul 31, 2025
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06364449
Responsible party
National Taiwan University Clinical Trial Center (Assistant professor, National Taiwan University Hospital) — Principal investigator
First posted
Apr 15, 2024
Start date
Oct 13, 2023
Primary completion
May 7, 2024
Completion
Jul 31, 2025 (estimated)
Last update
Jun 19, 2025

Study contacts

Chih-Yang Chan, phd
Contact
chanchihyang@gmail.com
+88672651147
Chih-Yang Chan, phd
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion